Home/Pipeline/Pb212-OPM-101

Pb212-OPM-101

Advanced Solid Tumors

Phase 1/2Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1/2

Status

Active

Company

Orano med

About Orano med

Orano Med is a clinical-stage biotech pioneering targeted alpha therapy (TAT) with lead-212, a highly potent but short-range alpha emitter designed to precisely destroy cancer cells while sparing healthy tissue. The company has built an integrated platform encompassing isotope production, preclinical development, and has initiated clinical trials. With operations in the US and France, Orano Med is positioning itself in the rapidly growing radioligand therapy market, aiming to address significant unmet needs in oncology.

View full company profile

Therapeutic Areas

Oncology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active